Evaluating Pharmacogenomics-Based Pharmacotherapy in Real-World Settings for Schizophrenia
NCT06700967 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 400
Last updated 2024-11-22
Summary
An 8-week, rater-blinded, real-world observational study to investigate the benefits of pharmacogenetics-based pharmacotherapy in patients suffering from schizophrenia.
Conditions
- Schizophenia Disorder
Sponsors & Collaborators
-
Shanghai Mental Health Center
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-12-01
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
Countries
- China
Study Locations
More Related Trials
-
A Pharmacogenetic Investigation of Antipsychotics in Schizophrenia and Schizophrenia-Like Psychoses
NCT00701753 ·Status: TERMINATED
-
Clinical Utility of Pharmacogenomics of Psychotropic Medications
NCT03907124 ·Status: WITHDRAWN ·Phase: PHASE4
-
Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment With Antipsychotics
NCT02573168 ·Status: COMPLETED ·Phase: NA
-
A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia
NCT05646264 ·Status: UNKNOWN ·Phase: PHASE4
-
Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients
NCT03451734 ·Status: COMPLETED
-
Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia
NCT02775864 ·Status: COMPLETED
-
Efficacy and Safety of Psychopharmacotherapy in Patients With Schizophrenia or Bipolar Disorders
NCT00330226 ·Status: UNKNOWN
-
The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment
NCT02650102 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Predictors of Functional Remission in Discharged Patients With Schizophrenia After Long-term Drug Discontinuation
NCT05667961 ·Status: COMPLETED
-
Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia
NCT01555697 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors
NCT00178932 ·Status: COMPLETED ·Phase: NA
-
The Genetic Basis of Inherited Neurologic Deficits in People With Schizophrenia
NCT00247637 ·Status: COMPLETED
-
Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia
NCT00063297 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Strategies to Improve Schizophrenia Treatment
NCT00156637 ·Status: COMPLETED ·Phase: NA
-
Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia
NCT05192304 ·Status: UNKNOWN ·Phase: PHASE1
-
A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia
NCT01626859 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
NCT01269710 ·Status: COMPLETED
-
Study of SPG302 in Adults With Schizophrenia
NCT06442462 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phenomics and Genomics of Clozapine Pharmacotherapy
NCT03253367 ·Status: UNKNOWN
-
The Relevance Between the microRNA-30e in Plasma and the Prognosis of Schizophrenia Patients
NCT03007303 ·Status: UNKNOWN
-
Genetic Study of Schizophrenia
NCT00001486 ·Status: COMPLETED
-
Neurophysiological Studies in Schizophrenia and Psychiatric Disorders
NCT01384604 ·Status: COMPLETED
-
A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia
NCT01812642 ·Status: COMPLETED ·Phase: PHASE2
-
Adverse Events and Genomics in Schizophrenia
NCT01966588 ·Status: UNKNOWN
-
Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm
NCT01016145 ·Status: UNKNOWN ·Phase: PHASE4